Related Experiment Video
Updated: Apr 30, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma]
Jingjing Wen1, Jiali Zhou1, Zhibin Liu1
1Department of Hematology and Research Laboratory of Hematology, West China Hospital of Sichuan University, Chengdu 610041, China.
Objective:
To Explore the poor prognostic factors of diffuse large B-cell lymphoma (DLBCL).
Methods:
The clinical data of 409 newly diagnosed patients with DLBCL from January 2000 to December 2010 were collected, and the prognostic factors by univariate and multivariate stratification were analyzed .
Results:
Of the 409 DLBCL patients, 244 were males and 165 females, the median age was 56(16-89) years old, the median follow-up time was 23(2-108) months. In univariate analysis, age, clinical stage, B symptoms, ECOG scores, the international prognostic index (IPI) scores, bone marrow involvement, low absolute lymphocyte count (ALC), high LDH, β2-MG>2 times of normal, regimen and therapeutic effect had significant influence on OS and PFS (P<0.05). Multivariate analysis showed that stage III-IV and high LDH were the poor prognostic factors of OS and PFS (P<0.05). When IPI scores were included, low ALC and IPI 3-5 scores were the poor predictors of OS and PFS in CHOP-like group (232 cases), revised IPI (R-IPI) was an independent poor predictors of OS and PFS in RCHOP-like group (177 cases).
Conclusion:
Stage III-IV and high LDH have negative influence on OS and PFS in patients with DLBCL, low ALC and IPI 3-5 scores affect OS and PFS in CHOP-like group, R-IPI affects OS and PFS in RCHOP-like group.
